Hu Weiqun, Dong Na, Huang Jinqiao, Ye Ben
Department of Otolaryngology, Affiliated Hospital of Putian University, Putian 351100, China.
J BUON. 2019 Nov-Dec;24(6):2429-2434.
Laryngeal cancer (LC) is one of the most ordinary head and neck cancers worldwide. In this study, the role of long non-coding RNA (lncRNA) PCAT1 in LC was explored.
PCAT1 expression in 50 paired tissue samples from LC patients was monitored by real-time quantitative polymerase chain reaction (RT-qPCR). Afterwards, function assays were conducted to explore how PCAT1 participated in metastasis of LC in vitro and in vivo. Then, bio-information software and luciferase assay were utilized to predict the possible target microRNA (miR) of PCAT1 in LC.
PCAT1 was obviously upregulated in LC tissues compared with adjacent tissues. Knockdown of PCAT1 inhibited the ability of cell migration and invasion in LC. Moreover, knockdown of PCAT1 inhibited tumor formation in vivo. Furthermore, miR-210-3p was sponged by PCAT1 in LC cells.
PCAT1 was first identified as a novel oncogene in LC and could promote LC cell migration and invasion by sponging miR-210-3p.
喉癌（LC）是全球最常见的头颈癌之一。本研究探讨了长链非编码RNA（lncRNA）PCAT1在喉癌中的作用。
通过实时定量聚合酶链反应（RT-qPCR）监测50对喉癌患者组织样本中PCAT1的表达。随后，进行功能分析以探究PCAT1在体外和体内如何参与喉癌转移。然后，利用生物信息软件和荧光素酶报告基因检测预测PCAT1在喉癌中可能的靶微小RNA（miR）。
与癌旁组织相比，PCAT1在喉癌组织中明显上调。敲低PCAT1可抑制喉癌细胞的迁移和侵袭能力。此外，敲低PCAT1可抑制体内肿瘤形成。此外，在喉癌细胞中PCAT1可吸附miR-210-3p。
PCAT1首次被鉴定为喉癌中的一种新型癌基因，可通过吸附miR-210-3p促进喉癌细胞迁移和侵袭。
